Plasma From Recovered COVID-19 Patients Inhibits Spike Protein Binding to ACE2 in a Microsphere-Based Inhibition Assay.
We present a microsphere-based flow cytometry assay that quantifies the ability of plasma to inhibit the binding of spike protein to angiotensin-converting enzyme 2. Plasma from 22 patients who had recovered from mild coronavirus disease 2019 (COVID-19) and expressed anti-spike protein trimer immunoglobulin G inhibited angiotensin-converting enzyme 2-spike protein binding ... to a greater degree than controls. The degree of inhibition was correlated with anti-spike protein immunoglobulin G levels, neutralizing titers in a pseudotyped lentiviral assay, and the presence of fever during illness. This inhibition assay may be broadly useful to quantify the functional antibody response of patients recovered from COVID-19 or vaccine recipients in a cell-free assay system.
Mesh Terms:
Adult, Aged, Angiotensin-Converting Enzyme 2, Antibodies, Neutralizing, Antibodies, Viral, Binding Sites, COVID-19, Female, HEK293 Cells, Humans, Male, Microspheres, Middle Aged, Plasma, Protein Binding, SARS-CoV-2, Serologic Tests, Spike Glycoprotein, Coronavirus, Young Adult
Adult, Aged, Angiotensin-Converting Enzyme 2, Antibodies, Neutralizing, Antibodies, Viral, Binding Sites, COVID-19, Female, HEK293 Cells, Humans, Male, Microspheres, Middle Aged, Plasma, Protein Binding, SARS-CoV-2, Serologic Tests, Spike Glycoprotein, Coronavirus, Young Adult
J Infect Dis
Date: Dec. 13, 2019
PubMed ID: 32798222
View in: Pubmed Google Scholar
Download Curated Data For This Publication
223040
Switch View:
- Interactions 1